Document is current
Any future updates will be listed below
-
Authors
Lawrence, Mitchell G. https://orcid.org/0000-0001-9520-3000
Taylor, Renea A. https://orcid.org/0000-0003-2609-2380
Cuffe, Georgia B. https://orcid.org/0000-0003-0491-5956
Ang, Lisa S. https://orcid.org/0000-0001-6140-4330
Clark, Ashlee K.
Goode, David L.
Porter, Laura H.
Le Magnen, Clémentine https://orcid.org/0000-0002-6084-6054
Navone, Nora M. https://orcid.org/0000-0001-8645-6890
Schalken, Jack A. https://orcid.org/0000-0001-8274-7797
Wang, Yuzhuo https://orcid.org/0000-0002-9749-8591
van Weerden, Wytske M. https://orcid.org/0000-0003-0324-4804
Corey, Eva https://orcid.org/0000-0002-9244-3807
Isaacs, John T. https://orcid.org/0000-0002-3854-4658
Nelson, Peter S. https://orcid.org/0000-0002-5451-5726
Risbridger, Gail P. https://orcid.org/0000-0003-3089-4028
- License Information
-
More Information
Article History
Accepted: 9 December 2022
First Online: 17 January 2023
Competing interests
: G.P.R., R.A.T. and M.G.L. have been involved in research collaborations with AstraZeneca and Pfizer. W.M.v.W. has been involved in research collaborations with Bayer. E.C. has received research funding under institutional sponsored research agreements from AbbVie, Bayer Pharmaceuticals, Forma Pharmaceutics Foghorn, Gilead, GSK, Janssen Research and Development, KronosBio, MacroGenics and Sanofi. P.S.N. has been a paid consultant to Astellas, Bristol Myers Squibb, Janssen and Pfizer for work unrelated to the present study. The remaining authors declare no competing interests.
